Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of CoronaVac in Children Aged 3-11 Years
NCT05198336Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of coronavac in coronavirus disease 2019 (COVID-19), sponsored by Sinovac Biotech Ltd.. Started Jan 2022; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05198336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198336.